. Author manuscript; available in PMC: 2014 Jan 13.

Published in final edited form as: Front Biosci (Schol Ed). 2012 Jan 1;4:520–531. doi: 10.2741/282

Table 1.

Completed clinical trials with CAR⁺ T cells

1^st Author, Year	Type of T cell	CAR construct	Cell Dose (T cells/m²)	Cancer/No. Pt.	Serious Adverse Events	Persistence	Anti-tumor response
Park, 2007 (24)	OKT3 activated T cells	CE7R-1^st gen. CAR plasmid with HyTK, nonviral transduction	10⁸ - 10⁹	Neuro-blastoma/ 6	None	1-42 days	1/6 PR
Kershaw, 2008 (65)	OKT3/allo-antigen activated T cells	α-folate receptor, 1^st gen. CAR, retroviral vector	3 × 10⁹ - 5 × 10¹⁰ (OKT3) 4 × 10⁹-1.69 × 10¹¹ (alloantigen)	Ovarian/ 14	None	Up to 3 wks (OKT3)12 mo. in one patient (alloantigen)	None reported
Till, 2008 (23)	OKT3 activated T cells	CD20, 1^st gen, CAR, nonviral transduction	10⁸ - 3.3 × 10⁹	CD20⁺ NHL/7	None	1-3 wks (clones) 5-9 wks (lines+ IL2)	5 eval: 4 SD, 1 PR
Pule, 2008 (25)	OKT3 activated T cells and EBV-specific CTLs	GD₂-CAR retroviral vector	2 × 10⁷ - 2 × 10⁸ of each product	Neuro-blastoma/ 11	None	Up to 3 wks for activated T cells; up to 6 mo. CTLs	8 eval: 4 response with 1 CR
Lamers, 2010 (64)		G250-1^st gen. CAR, retroviral vector	0.38 - 2.13 × 10⁹	Renal/ 11	Liver	Up to 53 days	None reported
Kochen-derfer, 2010 (28)		CD19, 2^nd gen. CAR, retroviral vector	4 × 10⁸ in 2 divided doses	Follicular/1	Absent Ig	27 wks	PR